https://www.selleckchem.com/pr....oducts/serotonin-hcl
Immune checkpoint inhibition (CPI) for metastatic colorectal cancer (mCRC) with deficient mismatch repair (dMMR) demonstrates high clinical activity that appears durable but the impact of CPI on pathological tumor response is unknown. In this retrospective analysis, our objective was to assess pathological response and clinical outcomes in dMMR mCRC patients treated with CPI prior to surgical resection of primary and/or metastatic tumor. Amongst 121 advanced dMMR mCRC patients treated with CPI at two institutions between November
Like
Comment
Share
